Impact of blood urea nitrogen for long-term risk stratification in patients with coronary artery disease undergoing percutaneous coronary intervention  by Kawabe, Masayuki et al.
IJC Heart & Vessels 4 (2014) 116–121
Contents lists available at ScienceDirect
IJC Heart & Vessels
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i j c -hear t -and-vesse lsImpact of blood urea nitrogen for long-term risk stratiﬁcation in patients
with coronary artery disease undergoing percutaneous
coronary interventionMasayuki Kawabe a, Akira Sato a,⁎, Tomoya Hoshi a, Shunsuke Sakai a, Daigo Hiraya a, Hiroaki Watabe b,
Yuki Kakefuda b, Mayu Ishibashi a, Daisuke Abe c, Noriyuki Takeyasu c, Kazutaka Aonuma a
a Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Japan
b Department of Cardiology, Tsukuba Medical Center Hospital, Tsukuba, Japan
c Department of Cardiology, Ibaraki Prefectural Central Hospital, Tomobe, Japan⁎ Corresponding author at: Cardiovascular Division, Fa
Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan. Tel./fax
E-mail address: asato@md.tsukuba.ac.jp (A. Sato).
http://dx.doi.org/10.1016/j.ijchv.2014.06.002
2214-7632/© 2014 The Authors. Published by Elsevier Irea b s t r a c ta r t i c l e i n f oArticle history:
Received 10 June 2014
Accepted 30 June 2014
Available online 6 July 2014
Keywords:
Blood urea nitrogen
Percutaneous coronary intervention
Estimated glomerular ﬁltration rate
Background: Few studies have examined the association between blood urea nitrogen (BUN) andmortality in pa-
tientswith coronary artery disease (CAD).We investigated the prognostic value of BUN concentration at hospital
admission in patients with CAD.
Methods: A total of 3641 patients with CAD who underwent percutaneous coronary intervention (PCI) were in-
cluded from April 2007 to June 2011. We measured BUN concentration at hospital admission and compared it
with long-term clinical outcome. Patients were classiﬁed into three groups according to BUN concentration of
b20 mg/dl, 20 to 25 mg/dl, or N25 mg/dl. Primary endpoint was all-cause death.
Results: During the follow-up period (median 15 months), 248 (6.8%) patients died. A higher BUN level was as-
sociatedwithmultivessel disease, lower ejection fraction, lower systolic blood pressure, and higher prevalence of
comorbidities. Cox regression analysis showed that patients with BUN of N25 mg/dl had a hazard ratio (HR) for
mortality of 2.73 (95%CI, 1.14 to 6.53; p= 0.023)with an estimated glomerularﬁltration rate (eGFR) of≥45 ml/
min/1.73m2 and aHRof 2.90 (95%CI, 1.75 to 4.82; p b 0.001)with an eGFR of b45 ml/min/1.73m2. Regardless of
acute coronary syndrome or stable CAD, BUN of N25 mg/dl was independently associated with higher mortality
(HR, 2.58; 95% CI, 1.43 to 4.64; p = 0.004 and HR, 2.16; 95% CI, 1.01 to 4.59; p = 0.044, respectively).
Conclusions: A BUN of N25 mg/dl was associated with long-term mortality in CAD patients who underwent PCI
independent of traditional cardiovascular risk factors and eGFR.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The mortality rate in coronary artery disease (CAD) correlates with
the severity of the illness, and some risk stratiﬁcation is needed. Well-
known risk factors include age,multivessel diseases, renal function, sys-
tolic blood pressure, anemia, levels of N-terminal pro-B-type natriuretic
peptide (NT-proBNP), B-type natriuretic peptide (BNP) and troponin,
and myocardial viability [1–5]. Recently, there has been a growing con-
cern regarding the importance of blood urea nitrogen (BUN) in cardio-
vascular disease. Several studies demonstrated that a high level of
BUN at admission is the best predictor of in-hospital mortality inculty of Medicine, University of
: +81 29 853 3143.
land Ltd. This is an open access articlpatients with acute heart failure [6,7], and BUN also serves as an im-
portant biomarker in critically ill patients without heart failure [8,9].
BUN may not only reﬂect homodynamic deterioration but also neu-
rohormonal activation such as that of the renin–angiotensin–aldo-
sterone system and sympathetic nervous system and arginine
vasopressin release [10,11]. However, serum creatinine (Cr) and es-
timated glomerular ﬁltration rate (eGFR) have shown only a weak
association with neurohormonal activation [10]. Although Cr and
eGFR are closely associated with short- and long-term mortalities
in patients with CAD [2], some studies indicated that BUN more
strongly relates to adverse outcomes than do Cr and eGFR in patients
with heart failure [12]. However, the prognostic value of BUN in pa-
tients with CAD undergoing PCI is unknown. Therefore, we evaluated
the impact of BUN concentration measured at hospital admission on
long-term mortality in a large cohort of patients with CAD who
underwent percutaneous intervention (PCI).e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1. Study population
Wepooled data from patients enrolled in the Ibaraki Cardiac Assess-
ment Study (ICAS) registry, amulticenter registry involving 12hospitals
in Ibaraki Prefecture, Japan. All traceable personal identiﬁers were re-
moved from the datasets before analysis to protect patient conﬁdential-
ity. We enrolled 3941 consecutive patients with CAD who underwent
PCI from April 2007 to June 2011. Patients with a BUN value not
measured at admission (n = 175) and those who underwent dialysis
(n = 125) were excluded. Thus, a total of 3641 patients were included
in this study. The study population consisted of 1715 patients with
acute coronary syndrome (ACS) and 1926 patients with stable CAD.
Bare metal stents were implanted in 782 (21%) patients, drug-eluting
stents were implanted in 2529 (70%) patients, and balloon angioplasty
without stenting was performed in 330 (9%) patients. ACS was deﬁned
as ST-elevation myocardial infarction, non-ST-elevation myocardial in-
farction, or unstable angina. The diagnosis of ACS was based on the uni-
versal deﬁnition of myocardial infarction [13]. CAD was diagnosed
based on the presence of N70% lumen obstruction of at least one of
the three major coronary arteries. Hypertension was deﬁned as the
presence of current treatment with antihypertensive drugs or other-
wise as a systolic blood pressure of N140 mm Hg and/or diastolic
blood pressure of N90 mm Hg. Dyslipidemia was deﬁned as current
treatment with cholesterol-lowering medications or low-density lipo-
protein (LDL) cholesterol value of N140 mg/dl and/or high-density li-
poprotein cholesterol value of b40 mg/dl. Diabetes mellitus was
deﬁned as a fasting glucose level of N126 mg/dl or treatment with
oral hypoglycemic agents or insulin. The eGFR was calculated with
the following equation: eGFR = 194 × (serum creatinine)(−1.094)
× (age)(−0.287) (×0.739 if female) [14]. Generally, a normal value
of BUN is 20 mg/dl or less. BUN with 25 mg/dl or more is signiﬁcantly
associated with poor prognosis in patients with myocardial infarction
[15]. Therefore patients were categorized into three groups accordingTable 1
Baseline characteristics of the patients.
BUN b 20 mg/dl BUN
Characteristic (n = 2784) (n
Age (year) 69 [61, 76] 74
Female gender (%) 22.3 23.
BMI (kg/m2) 24.2 [22.3, 26.5] 23.
SBP (mm Hg) 136 [120, 154] 135
DBP (mm Hg) 77 [67, 86] 74
LVEF (%) 63 [51, 68] 61
CRP (mg/dl) 0.16 [0.07, 0.34] 0.1
eGFR (ml/min/1.73 m2) 54.3 [46.6, 64.5] 42.
LDL cholesterol (mg/dl) 113 [91, 137] 107
Hemoglobin (g/dl) 14.0 [12.8, 15.1] 13.
Hypertension (%) 67.4 70.
Dyslipidemia (%) 57.7 51.
Diabetes mellitus (%) 36.3 41.
Prior MI (%) 17.3 18.
Prior HF (%) 4.1 7.7
Multivessel disease (%) 28.7 33.
ACS (%) 46.6 47.
Medication on admission
Beta blockers (%) 43.1 47.
ACE inhibitor (%) 23.8 23.
ARB (%) 35.2 44.
Statin (%) 70.4 67.
Diuretics (%) 13.3 29.
Values are reported as the medians [interquartile range], or %.
ACE = angiotensin converting enzyme, ACS = acute coronary syndrome, ARB = angiotensin r
artery bypass graft, Cr = creatinine, DBP = diastolic blood pressure, HF = heart failure, eGFR
tricular ejection fraction, MI = myocardial infarction, PCI = percutaneous coronary interventito BUN concentration measured at hospital admission: BUN of
b20 mg/dl, BUN of 20 to 25 mg/dl, and BUN of N25 mg/dl.
2.2. Coronary angiography and PCI procedure
PCI was performed according to standard techniques. All patients re-
ceived treatmentwith aspirin (100 mg/day) and clopidogrel (75 mg/day
following a 300-mg loading dose) or ticlopidine (200 mg/day). A glyco-
protein IIb/IIIa receptor inhibitor is not yet available in Japan. Operators
selected interventional devices and performed PCI through either the ra-
dial, brachial, or femoral artery using 6–7 French catheters. A low osmo-
lality, non-ionic contrast agent was used (iopamidol 350 mgI/ml:
Schering AG, Berlin, Germany). Before starting the procedure, heparin
8000 units was given intravenously, and the activated clotting time
was maintained at N300 s. The standard of care at discharge was to pre-
scribe clopidogrel for 1 year to all patients treated with drug-eluting
stents, whereas clopidogrel was prescribed for at least 3 months to pa-
tients treated with bare metal stents. Aspirin was continued indeﬁnitely
unless complications occurred. Informed consent was obtained from all
patients, and approval for this study was granted by each institution's
ethics committee. All adverse events were conﬁrmed by reviewing the
medical records of the patients followed at each institution.
2.3. Endpoints and deﬁnitions
The primary endpoint of our study was death from any cause. The
secondary endpoints included death from cardiovascular causes, con-
gestive heart failure, myocardial infarction, stroke, revascularization,
and a composite of these causes. Target vessel revascularizationwas de-
ﬁned as coronary bypass surgery or repeat PCI performed during the
follow-up period because of symptoms or signs of myocardial ischemia
in the presence of angiographic restenosis. Congestive heart failure was
deﬁned as admission to hospital for worsening heart failure requiring
intravenous drug treatment. Stroke was deﬁned as cerebral infarction,20–25 mg/dl BUN N 25 mg/dl
= 527) (n = 330) p value
[67, 80] 77 [68, 83] b0.001
6 27.0 0.140
8 [21.8, 26.2] 23.4 [21.4, 25.5] b0.001
[118, 151] 132 [111, 149] b0.001
[64, 84] 70 [61, 80] b0.001
[48, 67] 55 [41, 65] b0.001
6 [0.07, 0.48] 0.37 [0.14, 2.05] b0.001
4 [35.0, 52.5] 31.3 [23.4, 42.2] b0.001
[85, 128] 103 [83, 125] b0.001
2 [12.0, 14.4] 12.5 [10.8, 14.1] b0.001
3 74.5 0.018
9 44.0 b0.001
5 44.7 0.002
6 17.5 0.757
14.1 b0.001
8 39.6 b0.001
3 54.4 0.027
8 42.5 0.125
0 28.1 0.188
2 40.3 b0.001
8 56.3 b0.001
1 47.6 b0.001
eceptor blocker, BMI = bodymass index, BUN = blood urea nitrogen, CABG = coronary
= estimated glomerular ﬁltration rate, LDL = low-density lipoprotein, LVEF = left ven-
on, SBP = systolic blood pressure.
Fig. 2. Kaplan–Meier curves for each blood urea nitrogen (BUN) group.
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computed tomography or magnetic resonance imaging.
2.4. Statistical analysis
Continuous variables are expressed as medians and interquartile
ranges, and categorical variables as numbers and percentages. Compar-
isons between groups weremade by Kruskal–Wallis test for continuous
variables and Pearson chi-square test for categorical variables. Survival
analysis was performed by applying the Kaplan–Meier method and
log-rank test. Univariate and multivariate Cox proportional hazards
models were used to assess the association between BUN andmortality.
Factors identiﬁed through univariate analysis (p b 0.05)were tested in a
multivariable Cox proportional hazards model. Analyses were per-
formed with BUN, in category, as categorical variables with the lower
category (BUN of b20 mg/dl) serving as the reference for the other
two BUN categories. All statistical analyses were performed with EZR
(Saitama Medical Center, Jichi Medical University, Japan), which is a
graphical user interface for the R statistical analysis program (The R
Foundation for Statistical Computing, version 2.13.0). A two-tailed p
value of b0.05 was considered to indicate statistical signiﬁcance.
3. Results
3.1. Clinical and procedural characteristics
Baseline demographic and clinical and angiographic characteristics
are shown in Table 1. Of the 3641 patients, 2784 (76%) patients had a
BUN of b20 mg/dl, 527 (14%) had a BUN of 20 to 25 mg/dl, and 330
(8%) patients had a BUN of N25 mg/dl. Patients with a higher BUN
weremore likely to have previous heart failure, stroke, hypertension, di-
abetes mellitus, dyslipidemia, worse baseline renal function, low body
mass index, low blood pressure, and a high C-reactive protein level.
Beta-blockers and angiotensin-converting enzyme inhibitors were
used regardless of BUN levels, but statins were used less in patients
with a higher BUN. Diuretics were more used in patients with a higher
BUN. The BUN level increased with the severity of angiographic disease.
3.2. BUN and clinical events
The median duration of follow-up was 15 months (interquartile
range, 8 to 28 months). During the follow-up period, 248 (6.8%) pa-
tients died. BUN concentration was 15.8 mg/dl (interquartile range,
12.9 to 19.3 mg/dl) in survivors and 19.0 mg/dl (interquartile range,
14.2 to 25.6 mg/dl) in non-survivors (p b 0.001). The relation betweenFig. 1. Relation between blood urea nitrogen (BUN) leveBUN and cardiac events during the follow-up periods is shown in Fig. 1.
Patientswith higher BUNweremore likely to suffer all-cause death, car-
diac death, congestive heart failure, and composite endpoints. However,
a higher BUN was not associated with the onset of stroke (p = 0.060),
myocardial infarction (p= 0.228), or required target vessel revascular-
ization (p= 0.456). Kaplan–Meier analysis revealed an increased mor-
tality rate in patients with higher BUN (p b 0.001) (Fig. 2).
3.3. Predictors of clinical events according to multivariate analysis
Multivariate analysis demonstrated that a BUN of N25 mg/dl was an
independent predictor of mortality (hazard ratio [HR], 2.39; 95% conﬁ-
dence interval [CI], 1.52 to 3.77; p b0.001) as compared with a BUN of
b20 mg/dl (Table 2). Survival curves for BUN stratiﬁed by eGFR are
shown in Fig. 3. A higher BUN was associated with mortality in both
eGFR groups. In this stratiﬁed analysis adjusted for covariates, in com-
parison with the group with a BUN of b20 mg/dl, patients with a BUN
of N25 mg/dl had a HR for mortality of 2.73 (95% CI, 1.14 to 6.53; p =
0.023) with an eGFR of ≥45 ml/min/1.73 m2 and a HR of 2.90 (95% CI,
1.75 to 4.82; p b 0.001) with an eGFR of b45 ml/min/1.73 m2
(Table 3). Regardless of whether patients had ACS or stable CAD, a
BUN of N25 mg/dl was independently associated with higher mortality
(HR, 2.58; 95% CI, 1.43 to 4.64; p = 0.004 and HR, 2.16; 95% CI, 1.01–
4.59; p = 0.044, respectively). A BUN of 20 to 25 mg/dl was notls and adverse events during the follow-up periods.
Table 2
Univariate and multivariate cox regression analysis of mortality.
Univariate Multivariate
Variables HR 95% CI p value HR 95% CI p value
BUN b20 mg/dl Reference Reference
BUN 20 to 25 mg/dl 1.80 1.24–2.61 b0.001 1.03 0.64–1.67 0.889
BUN N25 mg/dl 5.29 3.86–7.25 b0.001 2.39 1.52–3.77 b0.001
ACS 2.16 1.64–2.83 b0.001 1.61 1.15–3.77 b0.001
Age (per year) 1.07 1.05–1.08 b0.001 1.04 1.02–1.06 b0.001
BMI (per kg/m2) 0.89 0.87–0.92 b0.001 0.91 0.87–0.94 b0.001
eGFR
(per ml/min/1.73 m2)
0.96 0.95–0.97 b0.001 0.97 0.96–0.99 b0.001
LVEF (per 10% increase) 0.59 0.48–0.71 b0.001 0.85 0.72–1.01 0.074
Hypertension 1.44 1.09–1.88 0.008 1.26 0.87–1.85 0.217
Dyslipidemia 2.38 1.78–3.12 b0.001 1.58 0.56–2.27 0.013
Diabetes mellitus 1.06 0.81–1.39 0.649
Multivessel disease 2.40 1.82–3.17 b0.001 2.05 1.46–2.90 b0.001
HR = hazard ratio, CI = conﬁdence interval.
See Table 1 for other abbreviations.
Table 3
Hazard ratios for mortality stratiﬁed by eGFR.
BUN b20 mg/dl BUN 20–25 mg/dl BUN N25 mg/dl
eGFR ≥45
(ml/min/1.73 m2)
HR 1.0
(Reference)
HR 0.62
(95% CI 0.22–1.73)
(p = 0.363)
HR 2.73
(95% CI 1.14–6.53)
(p = 0.023)
eGFR b45
(ml/min/1.73 m2)
HR 1.0
(Reference)
HR 1.35
(95% CI 0.76–2.39)
(p = 0.300)
HR 2.90
(95% CI 1.75–4.82)
(p b 0.001)
Adjusted for ACS, age, BMI, eGFR, LVEF, hypertension, dyslipidemia and multivessel disease.
See Tables 1 and 2 for abbreviations.
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HR, 0.99; 95% CI, 0.47–2.09; p = 0.990, respectively) (Table 4, Fig. 4).
4. Discussion
The main ﬁndings of the present study were that BUNwas a signiﬁ-
cant predictor of long-termmortality in patientswhounderwent PCI re-
gardless of the presence of ACS or stable CAD. Especially, a BUN of
N25 mg/dl was associated with long-term mortality independent of
eGFR and other clinical characteristics. The present study identiﬁed a
prognostic value of BUN in the patients with ACS or stable CAD who
underwent PCI in our multicenter cohort registry.
4.1. BUN and clinical events
At the time of renal dysfunction, the BUN rises along with Cr and
eGFR. However, many non-renal factors inﬂuence these biomarkers,
and BUN especially is more strongly subjected to the inﬂuence of
non-renal factors than are Cr and eGFR [16]. Hemodynamic instability
induced by congestive heart failure results in a decrease in renal perfu-
sion, increasing the reabsorption of urea and reducing the renal excre-
tion of urea, promotes activation of the renin–angiotensin–aldosterone
system and sympathetic nervous system and increases arginineFig. 3. Kaplan–Meier curves for each blood urea nitrogen (BUN) grvasopressin release, and raises BUN concentration [17,18]. These
neurohormones are associated with cardiovascular mortality,
whereas Cr and eGFR have a less pronounced relation with neuro-
hormonal activation [19]. Thus, BUN represents the best surrogate
marker of neurohormonal activation in congestive heart failure.
We found a higher BUN in patients with CAD to be signiﬁcantly asso-
ciated with mortality because a higher BUN in patients with CAD
was associated with multivessel disease and lower left ventricular
ejection fraction, which may result in hemodynamic instability lead-
ing to congestive heart failure.
Several previous studies have demonstrated that renal dysfunction
is a strong predictor of death in patientswith CAD [2,20], but these stud-
ies deﬁned renal dysfunction according to Cr, creatinine clearance, or
eGFR, and BUN was not taken into consideration. Although there have
been studies on the impact of BUN onmortality of patients with conges-
tive heart failure [6,7,12], there are few studies on the association be-
tween BUN and mortality of patients with CAD. A higher BUN was
associated with increased mortality in patients with ACS independent
of eGFR [15,21,22]. These studies included only patients with ACS, and
the association between BUN and prognosis of patients with stable
CAD was unknown. The present study demonstrated that a higher
BUN in patients with stable CAD was independently associated with a
higher mortality as in patients with ACS. To our knowledge, no other
study has examined BUN as a prognostic predictor in patients with sta-
ble CAD undergoing PCI, andwe foundBUN to be a prognosticmarker of
long-term mortality independent of other markers.
Many national guidelines consider eGFR calculated by the MDRD
equation to be the most reliable measure of renal function, and it is
strongly associated with prognosis of cardiovascular patients [14,23].
A previous study has demonstrated that an eGFR of b45 ml/min/1.73oup stratiﬁed by estimated glomerular ﬁltration rate (eGFR).
Table 4
Hazard ratios for mortality stratiﬁed by ACS or stable CAD.
BUN b20 mg/dl BUN 20–25 mg/dl BUN N25 mg/dl
ACS HR 1.0
(Reference)
HR 1.10
(95% CI 0.58–2.07)
(p = 0.763)
HR 2.58
(95% CI 1.43–4.64)
(p = 0.004)
Stable CAD HR 1.0
(Reference)
HR 0.99
(95% CI 0.47–2.09)
(p = 0.990)
HR 2.16
(95% CI 1.01–4.59)
(p = 0.044)
Adjusted for ACS, age, BMI, eGFR, LVEF, hypertension, dyslipidemia and multivessel disease.
See Tables 1 and 2 for abbreviations.
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excluded patients with poor renal function [14], our ﬁndings suggested
that even if renal function is poor, i.e., eGFR is b45 ml/min/1.73 m2, a
BUN of N25 mg/dl was independently associated with mortality. The
present study demonstrated that a higher BUNwas associated with tra-
ditional coronary risk factors such as diabetes mellitus, dyslipidemia,
and hypertension. Moreover, the proportions of patients with lower
LVEF and multivessel diseases were increased in those with higher
BUN. Although these traditional risk factors did not directly relate to a
higher BUN, they result in multivessel disease and decreased LVEF
that brings about impaired renal ﬂow, and, as a result, may lead to a
higher BUN. As in cardiovascular diseases, a higher BUN in non-
cardiovascular diseases is also related to neurohumoral response to
renal hypoperfusion. In addition, an increased BUN has a negative im-
pact on patient survival by reﬂecting the extent of catabolism. In the
acute phase, this catabolism may be beneﬁcial, providing amino acids
for hepatic gluconeogenesis and for synthesis of proteins involved in
immune functions, but persistent hypercatabolism in critically ill pa-
tients results in decreased immune function, which leads to increased
mortality [9]. Thus, BUN is considered an integral marker of tissue ne-
crosis, protein catabolism, and renal perfusion.4.2. Study limitations
Our study has several limitations. This was a nonrandomized, retro-
spective, and observational study, and as with any observational stud-
ies, it is possible that unrecognized and recognized confounding
factors may inﬂuence the data despite adjusting for these factors. The
study ﬁndings are based on a single BUN measurement. As a result,
time-dependant changes in BUN concentration remain unaccounted
for. Additional factors that affect BUN concentration, such as doses andFig. 4. Kaplan–Meier curves for each blood urea nitrogen (BUN) group stratiﬁedtypes of diuretics (e.g., loop diuretics, thiazide, spironolactone), and
contrast-induced nephropathy, were not assessed. Because NT-
proBNP, BNP, and high-sensitivity troponin assays were not available
for the majority of the patients in this study, we could not adjust for
these biomarkers.
5. Conclusions
In patients with both ACS and stable CAD, an elevated BUN mea-
sured at hospital admissionwas associatedwith increasedmortality, in-
dependent of traditional cardiovascular risk factors and eGFR. In this
setting, neurohormonal activation that results in renal hypoperfusion
and catabolism may play an important role in the elevation of BUN.
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